CluePoints’ Launch of Post-COVID Trial Assurance Solution
CluePoints has launched a new Post-COVID Trial Assurance Solution as part of its mission to build safer, more efficient trials for patients, sponsors and CROs.
The new CluePoints Post-COVID Trial Assurance Solution offers study teams the opportunity to assess the quality of their data within a defined timeline and with limited resources. It goes beyond traditional key risk indicators to evaluate 100% of the clinical data to assess expected risks, while also identifying data anomalies which might indicate unexpected risks—surfacing issues which can be found by leveraging CluePoints’ Central Statistical Monitoring Platform.
Furthermore, CluePoints can provide Data Scientists to do all the heavy lifting and work with the study team to support plans to identify and resolve issues and document what’s been done to mitigate the risks.
The Post-COVID Trial Assurance Solution includes (subject to expert consultation as to what will work best on your specific study or studies):
- Comprehensive Central Statistical Analysis
The comprehensive statistical analysis provides a complete unsupervised analysis of all clinical data to uncover unknown risks in your trial
- Key Risk Indicators (KRIs)
The Key Risk Indicator module provides a convenient way to monitor how sites are performing versus the metrics that are important to the trial
- Patient Profiles
By coupling Patient Profiles with Central Statistical Monitoring, patients can be ranked by their relative degree of atypicality, allowing clinical teams to get the patients that need it reviewed faster
- Duplicate Patients
If the existence of ‘Professional Patients’ participating in the trial is a concern, CluePoints’ Duplicate Patients module can identify them so that any sign of enrolment abuse can be investigated and addressed
For more information, click here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
